Prothrombotic disorders in abdominal vein thrombosis

Netherlands Journal of Medicine

Volumn 70, Issue 9, 2012, Pages 400-405

  Leebeek, F W G ^a   Smalberg, J H ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Budd Chiari syndrome; Myeloproliferative neoplasm; Portal vein thrombosis; Splanchnic vein thrombosis; Thrombophilia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; ECULIZUMAB; HYDROXYUREA; JANUS KINASE 2; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ABDOMINAL VEIN THROMBOSIS; ANTICOAGULANT THERAPY; BONE MARROW BIOPSY; BUDD CHIARI SYNDROME; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MYELOPROLIFERATIVE NEOPLASM; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOPHILIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

BUDD-CHIARI SYNDROME; HUMANS; MESENTERIC VASCULAR OCCLUSION; MESENTERIC VEINS; MYELOPROLIFERATIVE DISORDERS; PORTAL VEIN; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 84869022666     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver D. Vascular disorders of the liver. Hepatology. 2009;49:1729-64.
2. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364-71.
3. Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med. 2008;66:334-9.
4. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729-64.
5. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167-75.
6. Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med. 2009;67:46-53.
7. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210-8.
8. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364-8.
9. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587-91.
10. Smalberg JH, Darwish Murad S, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006;91:1712-3.
11. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41:603-8.
12. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011;31:485-93.
13. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost. 2008;99:675-82.
14. Amitrano L, Ames PR, Guardascione MA, et al. Antiphospholipid antibodies and antiphospholipid syndrome: role in portal vein thrombosis in patients with and without liver cirrhosis. Clin Appl Thromb Hemost. 2011;17:367-70.
15. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
16. Martinelli I, Primignani M, Aghemo A, et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol. 2009;50:916-22.
17. Raffa S, Reverter JC, Seijo S, et al. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:72-8.
18. de Bruijne EL, Darwish Murad S, de Maat MP, et al. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost. 2007;97:181-5.
19. Hoekstra J, Guimaraes AH, Leebeek FW, et al. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood. 2010;115:388-95.
20. Talens S, Hoekstra J, Dirkx SP, et al. Proteomic analysis reveals that apolipoprotein a1 levels are decreased in patients with Budd-Chiari syndrome. J Hepatol. 2011;54:908-14.
21. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-5.
22. Eichinger S, Hron G, Hirschl M, et al. Prediction of recurrent venous thromboembolism by measuring ProC Global. Thromb Haemost. 2007;98:1232-6.
23. Koopmans SM, van Marion AM, Schouten HC. Myeloproliferative neoplasia: a review of clinical criteria and treatment. Neth J Med. 2012;70:159-67.
24. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922-9.
25. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55-61.
26. Smalberg JH, Arends I, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari Syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012:accepted for publication.
27. Janssen HL, Leebeek FW. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology. 2006;44:1391-3.
28. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020-8.
29. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5:642-5.
30. Hoekstra J, Leebeek FW, Plessier A, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol. 2009;51:696-706.
31. Brodsky RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008;148:587-95.
32. Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost. 2012;10:1-10.
33. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology. 1986;90:807-11.
34. Pietrobattista A, Luciani M, Abraldes JG, et al. Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders. World J Gastroenterol. 2010;16:6123-7.
35. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490-7.
36. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102:2464-70.
37. Spaander M, Hoekstra J, Hansen BE, Janssen HL. Effect of anticoagulation therapy in patients with non cirrhotic extrahepatic portal vein thrombosis. Hepatology. 2010;52:1068A-A.
38. Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol. 2012;56 Suppl 1:S25-38.
39. Hoekstra J, Bresser EL, Smalberg JH, Spaander MCW, Leebeek FWG, Janssen HLA. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost. 2011;9:2208-14.